‘D+Q senolytic’ directory
- See Also
-
Links
- “Senolytic Therapy in Mild Alzheimer’s Disease: a Phase 1 Feasibility Trial”, Gonzales et al 2023
- “Long-Term Dasatinib plus Quercetin Effects on Aging Outcomes and Inflammation in Nonhuman Primates: Implications for Senolytic Clinical Trial Design”, Ruggiero et al 2023
- “Senolytic Drugs, Dasatinib and Quercetin, Attenuate Adipose Tissue Inflammation, and Ameliorate Metabolic Function in Old Age”, Islam et al 2023
- “Senolytics Dasatinib and Quercetin in Idiopathic Pulmonary Fibrosis: Results of a Phase I, Single-Blind, Single-Center, Randomized, Placebo-Controlled Pilot Trial on Feasibility and Tolerability”, Nambiar et al 2023
- “Combination of Dasatinib and Quercetin Improves Cognitive Abilities in Aged Male Wistar Rats, Alleviates Inflammation and Changes Hippocampal Synaptic Plasticity and Histone H3 Methylation Profile”, Krzystyniak et al 2022
- “Deletion of SA Β-Gal+ Cells Using Senolytics Improves Muscle Regeneration in Old Mice”, Dungan et al 2021
- “Targeting p21Cip1 Highly Expressing Cells in Adipose Tissue Alleviates Insulin Resistance in Obesity”, Wang et al 2021
- “Sexual Dimorphic Responses of C57BL/6 Mice to Fisetin or Dasatinib and Quercetin Cocktail Oral Treatment”, Fang et al 2021
- “A Collective Analysis of Lifespan-Extending Compounds in Diverse Model Organisms, and of Species Whose Lifespan Can Be Extended the Most by the Application of Compounds”, Berkel & Cacan 2021
- “Modulation of Fracture Healing by the Transient Accumulation of Senescent Cells”, Saul et al 2021
- “Whole-Body Senescent Cell Clearance Alleviates Age-Related Brain Inflammation and Cognitive Impairment in Mice”, Ogrodnik et al 2021
- “Senolytics Decrease Senescent Cells in Humans: Preliminary Report from a Clinical Trial of Dasatinib plus Quercetin in Individuals With Diabetic Kidney Disease”, Hickson et al 2019
- “Dasatinib and Quercetin: Short-Term Simultaneous Administration Improves Physical Capacity in Humans”, Jaba & David 2019
- “Senolytics in Idiopathic Pulmonary Fibrosis: Results from a First-In-Human, Open-Label, Pilot Study”, Justice et al 2019
- “Investigation of Quercetin and Hyperoside As Senolytics in Adult Human Endothelial Cells”, Hwang et al 2017
- Wikipedia
- Miscellaneous
- Bibliography
See Also
Links
“Senolytic Therapy in Mild Alzheimer’s Disease: a Phase 1 Feasibility Trial”, Gonzales et al 2023
Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial
“Long-Term Dasatinib plus Quercetin Effects on Aging Outcomes and Inflammation in Nonhuman Primates: Implications for Senolytic Clinical Trial Design”, Ruggiero et al 2023
“Senolytic Drugs, Dasatinib and Quercetin, Attenuate Adipose Tissue Inflammation, and Ameliorate Metabolic Function in Old Age”, Islam et al 2023
“Senolytics Dasatinib and Quercetin in Idiopathic Pulmonary Fibrosis: Results of a Phase I, Single-Blind, Single-Center, Randomized, Placebo-Controlled Pilot Trial on Feasibility and Tolerability”, Nambiar et al 2023
“Combination of Dasatinib and Quercetin Improves Cognitive Abilities in Aged Male Wistar Rats, Alleviates Inflammation and Changes Hippocampal Synaptic Plasticity and Histone H3 Methylation Profile”, Krzystyniak et al 2022
“Deletion of SA Β-Gal+ Cells Using Senolytics Improves Muscle Regeneration in Old Mice”, Dungan et al 2021
Deletion of SA β-Gal+ cells using senolytics improves muscle regeneration in old mice
“Targeting p21Cip1 Highly Expressing Cells in Adipose Tissue Alleviates Insulin Resistance in Obesity”, Wang et al 2021
Targeting p21Cip1 highly expressing cells in adipose tissue alleviates insulin resistance in obesity
“Sexual Dimorphic Responses of C57BL/6 Mice to Fisetin or Dasatinib and Quercetin Cocktail Oral Treatment”, Fang et al 2021
“A Collective Analysis of Lifespan-Extending Compounds in Diverse Model Organisms, and of Species Whose Lifespan Can Be Extended the Most by the Application of Compounds”, Berkel & Cacan 2021
“Modulation of Fracture Healing by the Transient Accumulation of Senescent Cells”, Saul et al 2021
Modulation of fracture healing by the transient accumulation of senescent cells
“Whole-Body Senescent Cell Clearance Alleviates Age-Related Brain Inflammation and Cognitive Impairment in Mice”, Ogrodnik et al 2021
“Senolytics Decrease Senescent Cells in Humans: Preliminary Report from a Clinical Trial of Dasatinib plus Quercetin in Individuals With Diabetic Kidney Disease”, Hickson et al 2019
“Dasatinib and Quercetin: Short-Term Simultaneous Administration Improves Physical Capacity in Humans”, Jaba & David 2019
Dasatinib and Quercetin: Short-Term Simultaneous Administration Improves Physical Capacity in Humans
“Senolytics in Idiopathic Pulmonary Fibrosis: Results from a First-In-Human, Open-Label, Pilot Study”, Justice et al 2019
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
“Investigation of Quercetin and Hyperoside As Senolytics in Adult Human Endothelial Cells”, Hwang et al 2017
Investigation of quercetin and hyperoside as senolytics in adult human endothelial cells
Wikipedia
Miscellaneous
Bibliography
-
2023-gonzales.pdf: “Senolytic Therapy in Mild Alzheimer’s Disease: a Phase 1 Feasibility Trial”, -
https://onlinelibrary.wiley.com/doi/10.1111/acel.13528: “Deletion of SA Β-Gal+ Cells Using Senolytics Improves Muscle Regeneration in Old Mice”,